嗜铬细胞瘤与副神经节瘤报告数据集:ICCR指南解读
国际癌症报告协作组织(ICCR)组织国际内分泌器官专家小组,针对嗜铬细胞瘤和副神经节瘤制定了病理标准化报告数据集。该数据集围绕核心与非核心要素(如临床激素状态、家族史、肿瘤多灶性、增殖分数、风险分层特征及辅助技术)给出解释与推荐,旨在实现全球病理报告统一并改善患者管理。
要点
- 采用ICCR数据集统一嗜铬细胞瘤/副神经节瘤病理报告要素。
- 报告应包含临床激素状态、家族史、肿瘤多灶性等核心要素。
- 增殖分数与风险分层特征有助于预后评估与临床管理。
核心结论
- ICCR数据集为嗜铬细胞瘤和副神经节瘤提供病理标准化报告指南。
研究设计与样本
- 由ICCR组织国际内分泌器官专家小组制定循证共识数据集。
主要发现
- 嗜铬细胞瘤和副神经节瘤不常见且在登记数据集中常被忽略。
- 近期认识到显著的遗传关联并开发了风险分层工具。
关键数值与推荐
- 数据集讨论核心与非核心要素,包括临床激素状态、家族史、肿瘤多灶性、增殖分数、风险分层特征及辅助技术。
临床怎么用
- 在全球病理界使用相似标准以获得更有意义的结果与管理数据。
局限性
- 恶性标准此前仅在存在转移性疾病时才有定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit to develop evidence-based, internationally agreed-upon standardized data sets for each anatomic site, to be used throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to improved patient management and enhanced epidemiological research. METHODS: Pheochromocytoma and paraganglioma are uncommon and are frequently overlooked in registry data sets. Malignant criteria have previously been defined only when there was metastatic disease. RESULTS: With recent recognition of a significant inheritance association and the development of risk stratification tools, this data set was created in order to obtain more meaningful outcomes and management data, using similar criteria across the global pathology community. Issues related to key core and non-core elements, especially clinical hormonal status, familial history, tumor focality, proliferative fraction, adverse or risk stratification features, and ancillary techniques, are discussed in the context of daily application to these types of specimens. CONCLUSIONS: The ICCR data set, developed by an international panel of endocrine organ specialists, establishes a pathology-standardized reporting guide for pheochromocytoma and paraganglioma.
引用
- Thompson LDR, Gill AJ, Asa SL, et al. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol. 2020. PMID: 32407815. doi:10.1016/j.humpath.2020.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。